Parenteral oestrogen in the treatment of prostate cancer: A systematic review

British Journal of Cancer

Volumn 98, Issue 4, 2008, Pages 697-707

  Norman, G ^a   Dean, M E ^a   Langley, R E ^b   Hodges, Z C ^a   Ritchie, G ^a   Parmar, M K B ^b   Sydes, M R ^b   Abel, P ^c   Eastwood, A J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Parenteral oestrogen; Prostate cancer; Systematic review

Indexed keywords

17 BETA DIETHYLESTRADIOL; BISPHOSPHONIC ACID DERIVATIVE; BUSERELIN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOXORUBICIN; ESTRADIOL; ESTRADIOL UNDECYLATE; ESTRAMUSTINE PHOSPHATE; ESTROGEN; ETHINYLESTRADIOL; FLUTAMIDE; GONADORELIN; GOSERELIN; POLYESTRADIOL PHOSPHATE; TESTOSTERONE; TRIPTORELIN; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALE; MONOTHERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; UNITED KINGDOM;

CLINICAL TRIALS AS TOPIC; ESTROGENS; HUMANS; INFUSIONS, PARENTERAL; MALE; PROSTATIC NEOPLASMS;

EID: 39449083468     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604230     Document Type: Article

References (50)

1. Abel P. PATCH: a randomised controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer, Vol 2007. National Research Register (ongoing)
2. Andersson L, Berlin T, Boman J, Collste L, Edsmyr F, Esposti PL, Gustafsson H, Hedlund PO, Hultgren L, Leander G, Nordle O, Norlen H, Tillegard P (1980) Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study. Scand J Urol Nephrol 55(Suppl): 143-145
3. Aro J (1991) Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate 18: 131-137
4. Aro J, Haapiainen R, Kajanti M, Rannikko S, Alfthan O (1988) Comparison of endocrine and radiation therapy in locally advanced prostatic cancer. Eur Urol 15: 182-186
5. Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS (1989) High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group. Br J Urol 63: 512-514
6. Aro J, Ruutu M, Juusela H, Hansson E, Permi J (1993) Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. Ann Chir Gynaecol 82(Suppl 206): 5-8
7. Aronson N, Seidenfeld J, Samson DJ, Albertson PC, Bayoumi AM, Bennett C, Brown A (1999) Relative Effectiveness and Cost-effectiveness of methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer. Vol 4. Evidence Report/Technology Assessment. Rockville, MD: Agency for Health Care Policy and Research
8. Bayoumi AM, Brown AD, Garber AM (2000) Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92: 1731-1739
9. Bishop MC, Lemberger RJ, Selby C, Lawrence WT (1989) Oestrogen dosage in prostatic cancer: the threshold effect? Br J Urol 64: 290-296
10. Byar DP (1973) The Veterans' Administration Cooperative Urological Research Group's study of cancer of the prostate. Cancer 32: 1126-1130
11. Cancer Research UK (2007) UK prostate cancer statistics. London: Cancer Research UK (cited 22 January 2008). Available at: http://info.cancerresearchuk. org/cancerstats/types/prostate/
12. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353: 878-882
13. Daehlin L, Damber JE, Von Schoultz B, Bergman B (1986) The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin. Br J Urol 58: 412-416
14. D'Amico AV, Denham JW, Crook J, Chen M-H, Goldhaber SZ, Lamb DS, Joseph D, Tai K-H, Malone S, Ludgate C, Steigler A, Kantoff PW (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25: 2420-2425
15. Dean ME, Norman G, Hodges Z, Ritchie G, Light K, Eastwood A, Langley R, Sydes M, Parmar M, Abel P (2006) Parenteral Oestrogens for Prostate Cancer: A Systematic Review of Clinical Effectiveness and Dose Response. York: Centre for Reviews and Dissemination, University of York
16. Grodstein F, Manson JE, Stampfer MJ (2001) Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann Intern Med 135: 1-8
17. Haapiainen R, Rannikko S, Alfthan O (1986) Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study. Br J Urol 58: 528-533
18. Haapiainen R, Rannikko S, Alfthan O (1990) Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group. Br J Urol 66: 94-97
19. Haapiainen R, Rannikko S, Ruutu M, Ala-Opas M, Hansson E, Juusela H, Permi J, Saarialho M, Viitanen J, Alfthan O (1991) Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer. Br J Urol 67: 184-187
20. Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E, Scandinavian Prostatic Cancer Group (2002) Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer. Scandinavian Prostatic Cancer Group (SPCG) Study no. 5. Scand J Urol Nephrol 36: 405-413
21. Hedlund PO, Mikkelsen I, Hahne B, Kihl B (2007) Parenteral estrogen vs. combined androgen deprivation in the treatment of metastatic prostate cancer. The final evaluation of the SPCG study. [abstract]. Scand J Urol Nephrol 41(Suppl 217): Abstract
22. Henriksson P, Carlstrom K, Pousette A, Gunnarsson PO, Johansson CJ, Eriksson B, Altersgard-Brorsson AK, Nordle O, Stege R (1999) Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. Prostate 40: 76-82
23. Henriksson P, Edhag O (1986) Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects. BMJ 293: 413-415
24. Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, Carlstrom K (1988) Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 13: 257-261
25. Henriksson P, Johansson SE (1987) Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen. Am J Epidemiol 125: 970-978
26. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613
27. Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (1980) Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol 52: 208-215
28. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12
29. Johansson JE, Andersson SO, Holmberg L, Bergstrom R (1991a) Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. J Urol 146: 1327-1333
30. Johansson JE, Andersson SO, Holmberg L, Bergstrom R (1991b) Primary orchiectomy versus estrogen therapy in advanced prostatic cancer- a randomized study: results after 7-10 years of followup. J Urol 145: 519-523
31. Keating NL, O'Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456
32. Krupski TL, Smith MR, Chan Lee W, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS (2004) Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 101: 541-549
33. Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE (2003) Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol 20: 137-146
34. Lukkarinen O, Kontturi M (1994) Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study. Scand J Urol Nephrol 28: 171-178
35. Lundgren R, Nordle O, Josefsson K, The South Sweden Prostate Cancer Study Group (1995) Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of follow-up. J Urol 153: 1580-1586
36. Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M, Finnprostate Group (2005) Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scand J Urol Nephrol 39: 294-300
37. Mikkola A, Aro J, Rannikko S, Ruutu M, Finnprostate G (2007) Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. Prostate 67: 447-455
38. Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO (1998) Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol 82: 63-68
39. Morganstein N, Doyle-Lindrud S, Goodin S, Shih J, Altscher A, Teller E, Zager R, Todd M, Durivage H, Dipaola RS (2004) A phase II salvage trial of transdermal estradiol in the treatment of hormone and chemotherapy refractory prostate cancer: a Cancer Institute of New Jersey Oncology Group Study NJ1803. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S): 4695
40. Ockrim J, El-Nasir L, Abel P (2006) Therapy insight: parenteral estrogen treatment for prostate cancer- a new dawn for an old therapy. Nat Clin Pract Oncol 3: 552-563
41. Ockrim JL, Lalani E-N, Aslam M, Standfield N, Abel PD (2006) Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit? BJU Int 97: 498-504
42. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD (2003) Transdermal estradiol therapy for advanced prostate cancer- forward to the past? J Urol 169: 1735-1737
43. Pande I, Francis RM (2001) Osteoporosis in men. Baillieres Best Pract Res Clin Rheumatol 15: 415-427
44. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA (2005) The economic consequences of prostate and bladder cancer in the UK. BJU Int 95: 59-63
45. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294: 238-244
46. Steg A, Benoit G, Maisonneuve P, Tallet F, Nahoul K, Sulatna Y, Raichwarg D, Limousinlamotte MA (1983) A comparative study of percutaneous 17 beta-estradiol and diethylstilbestrol in the treatment of prostatic cancer. Ann Urol (Paris) 17: 197-202
47. Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A (1988) Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol 11(Suppl 2): S101-S103
48. Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, von Schoultz B (1989) Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens. Prostate 14: 183-188
49. Turgeon JL, McDonnell DP, Martin KA, Wise PM (2004) Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304: 1269-1273
50. von Schoultz B, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R (1989) Estrogen therapy and liver function- metabolic effects of oral and parenteral administration. Prostate 14: 389-395